natgillin/translations-raw huggingface dataset:
a second component, comprising a nicotine active which is a nicotine oil, pre-neutralized enteric polymer which is a poly(ethylacrylate -methacrylic acid) copolymer, and a plasticizer. 
drugu komponentu, koja sadrži aktivni nikotin, koji je nikotinsko ulje, preneutralizirani enterički polimer koji je poli(etilakrilat-metakrilno kiselinski) kopolimer, te plastifikator.
neutralizing an enteric polymer which is a poly(ethylacrylate -methacrylic acid) copolymer by mixing with an alkaline neutralizing agent in the presence of a solvent to render a polymeric mixture; 
neutraliziranja enteričkog polimera koji je poli(etilakrilat-metakrilno kiselinski) kopolimer miješanjem s alkalnim neutralizirajućim sredstvomu prisutnosti otapala kako bi se dobilo smjesu polimera;
casting the buffer mixture onto the polymeric film rendering a coated polymeric film; and 
lijevanja puferske smjese na polimerni film, čime se dobije obloženi polimerni film; i
The pharmaceutical composition according to any of the preceding claims, which contains the first and the second pharmacologically active ingredient in such a weight ratio that they will exert a synergistic therapeutic effect upon administration to a patient. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži prvi i drugi farmakološki aktivni sastojak u takvom težinskom omjeru da posjeduju sinergistički terapijski učinak prilikom primjene na pacijentu.
peripheral, central or muscle skeletal pain; and/or 
periferna, centralna ili muskuloskeletalna bol; i/ili
post-operative (post-surgical), cancer or inflammatory pain. 
postoperativna (nakon kirurškog zahvata), bol uzrokovana rakom ili upalna bol.
The pharmaceutical dosage form according to any of claims 7 to 10, which is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Farmaceutski oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 7 do 10, naznačen time što je namijenjen oralnoj, intravenskoj, intraperitonealnoj. transdermalnoj, intratekalnoj, intramuskularnoj, intranazalnoj, transmukozalnoj, supkutanoj ili rektalnoj primjeni.
The kit according to claim 12, wherein the first and the second pharmaceutical dosage form are adapted for simultaneous or sequential administration, either by the same or a different pathway of administration. 
Komplet u skladu s patentnim zahtjevom 12, naznačen time što su prvi i drugi farmaceutski oblik doziranja prilagođeni za istodobnu ili uzastopnu primjenu, bilo istim ili različitim načinom primjene.
The method of Claim 1 wherein the cell culture supernatant is maintained at a pH that is set at X±0.05 wherein X has a value of from 7.15 to 7.20, such as wherein the pH is set at 7.20±0.05, 7.20±0.03, 7.20±0.01, 7.20, 7.15±0.05, 7.15±0.03, 7.15±0.01 or 7.15, with the proviso that the pH is set at greater than 7.10. 
Postupak u skladu s patentnim zahtjevom 1 pri čemu se supernatant kulture stanica održava na temperaturi koja je podešena na 36 ± 0.9°C. Postupak u skladu s patentnim zahtjevom 1 ili 3, pri čemu se supernatant kulture stanica održava na pH X±0.05 pri čemu X ima vrijednost od 7.15 do 7.20, s pretpostavkom da je pH podešen na vrijednost višu od 7.10.
The bicomponent fiber of claims 1-3, wherein the second polymer component prior to being subjected to heat bonding has a softening temperature that is at least 5° C less than a softening temperature of the first polymer component. 
Postupak prema zahtjevu 1, naznačen time, da drugi polimerni sastojak prije spajanja, ima temperaturu omekšavanja koja je barem 5°C manja nego temperatura omekšavanja prvog polimernog sastojka.
The method according to claim 2, wherein the biomass comprises or originates from sugar cane, sugar beet, sweet sorghum, corn, wheat, barley, rye, sorghum, triticale, potato, sweet potato cassava, or a mixture thereof. 
Upotreba u skladu s patentnim zahtjevom 4, naznačena time što biomasa sadrži ili potječe iz šećerne trske, šećerne repe, slatkog sirka, kukuruza, pšenice, ječma, raži, sirka, tritikala, krumpira, slatkog krumpira, manioke, ili njihove smjese.
The method according to of claim 11, wherein the MDO film has a tensile creep in the machine direction of about 0.10% to about 0.50% per μm thickness of the film, as measured in accordance with ISO 899-1-2003 with following conditions: sample width of 15 mm, grip distance of 100 mm, a load of 2300 g, 24 hours, and at 23° C. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da je vrijednost vlačnog puzanja MDO filma u smjeru stroja oko 0,10 % do oko 0,50 % po um debljine filma, izmjereno u skladu s ISO 899-1-2003 pri sljedećim uvjetima: širina uzorka 15 mm, širina stezaljki 100 mm, opterećenje 2300 g, 24 sata, pri 23 °C.
The packaged product according to claim 19, wherein the compressible product is a mineral wool product. The packaged product according to claim 19, wherein the MDO film has a tensile creep in the machine direction of about 0.10% to about 0.50% per μm thickness of the film, as measured in accordance with ISO 899-1-2003 with following conditions: sample width of 15 mm, grip distance of 100 mm, a load of 2300 g, 24 hours, and at 23° C. 
Pakirani proizvod u skladu s bilo kojim od patentnih zahtjeva 9, 11 ili 12, ili MDO film u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačen time, da MDO film ima vrijednost vlačnog puzanja u smjeru stroja od oko 0,10% do oko 0,50% po um debljine filma, izmjereno u skladu s ISO 899-1-2003 pri sljedećim uvjetima: širina uzorka od 15 mm, udaljenost prihvata od 100 mm, opterećenje od 2300 g, 24 sata i na 23 °C.
wherein: a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond, R2 is not H; 
Spoj definiran formulom 1 [image], gdje a, b i c, međusobno neovisno, odgovarajuće označuju jednostruku vezu ili dvostruku vezu, uz uvjet da najmanje jedan od a, b i c predstavlja dvostruku vezu, te uz uvjet da ako je a jednostruka veza, a b je dvostruka veza, R2 nije H;
is, in case of c being a single bond, either hydrogen or C1 to C6 alkyl, or in case of c being a double bond, CHR5, wherein R5 is the same as defined before; and 
je, u slučaju ako je c jednostruka veza, bilo vodik ili C1 do C6 alkil, ili u slučaju ako je c dvostruka veza, CHR5, gdje je R5 isti kao što je definirano ranije;
an active substance selected from the group consisting of antibodies directed against VEGF, VEGFR or soluble VEGFR/VEGFR hybrids, and oncogenic tyrosine kinase inhibitors, and 
aktivnu tvar koju se bira iz skupine koju čine protutijela usmjerena protiv VEGF-a, VEGFR-a ili topljivih hibrida VEGFR/VEGFR, te inhibitori tirozinskih kinaza, i
an absorbance determining section for determining any one of a plurality of average values calculated by the average value calculating section to be absorbance for performing a sample analysis. 
određivanje bilo koje od mnoštva prosječnih vrijednosti izračunatih pomoću (iii) da bude apsorbancija za provođenje analize uzorka.
Soaking the solid product stream in vapor or liquid water or mixture thereof in the temperature range of 100°C to 210°C for 1 minute to 24 hours to create a second soaked biomass containing a dry content and a soaked liquid; 
namakanja prve struje krutina u pari ili tekućoj vodi ili njihovoj smjesi na rasponu temperatura od 100 °C do 210 °C, kako bi se dobilo drugu namočenu biomasu, koja sadrži suhi sadržaj i namočenu tekućinu;
A process according to claim 1, wherein the weight of sugars in the pre-soaked liquid stream relative to the weight of the total sugars of the ligno-cellulosic biomass in the feedstream are less than a value selected from the group consisting of 5 weight %, 2.5 weight %, and 1 weight %. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je težina šećera u struji prednamočene tekućine u odnosu na težinu šećera u ligno-celuloznoj biomasi u dovodnoj struji manja od vrijednosti koju se bira iz skupine koju čine 5%, težinski, 2,5%, težinski, i 1%, težinski.
The process according to claims 1 or 2, wherein the pre-soaking is done for a time less than 48 hours. 
Postupak u skladu s patentnim zahtjevima 1 do 2, naznačen time što se prednamakanje vrši u vremenu kraćem od 48 sati.
The process of any of claims 1 to 4, wherein the soaked liquid stream is filtered by nano-filtration. The process according to claim 5, wherein the at least a portion of the soaked liquid has an instantaneous flux greater than 7 L/h-m2, wherein the instantaneous flux is the flux when 72L of a 190L aliquot of the at least a portion of the soaked liquid have passed through a spiral nano-filter membrane conforming to the specifications that the membrane is a polyamide type thin film composite on polyester, has a magnesium sulfate rejection of greater than or equal to 98% when measured on 2000ppm magnesium sulfate in water at 9 bar and 25°C and having an outer diameter of 64.0 to 65.0 mm, a length of 432mm and an inside diameter of 21mm, the membrane having a cross-flow of 1.3-1.8 m3/h with a maximum pressure drop of 0.6 bar at 1cP and design membrane area of 0.7 m2. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što u najmanju ruku dio namočene tekućine ima trenutni protok veći od 7 l/h-m2, gdje je trenutni protok protok kada se 72 l alikvota od 190 l u najmanju ruku dijela namočene tekućine propusti kroz membranu spiralnog nanofiltra, usklađenu sa specifikacijama, prema kojima je membrana tankoslojni kompozit poliamidnog tipa na poliesteru, ima odbijanje magnezijevog sulfata veće od ili jednako 98% kada se mjeri uz 2000 ppm magnezijevog sulfate u vodi, pod tlakom od 9 bar, na 25 °C, te ima vanjski promjer od 64,0 do 65,0 mm, duljinu od 432 mm, a unutarnji promjer od 21 mm, gdje membrana ima poprečni protok od 1,3-1,8 m3/h, uz maksimalan pad tlaka od 0,6 bar na 1 cP i dizajniranu površinu membrane od 0,7 m2.
a connection portion (122) coupled to the projection (118); 
spojni dio (122) spojen na izbočinu (118);
The cap (104) of at least one of the preceding claims, wherein the opening (108) has a profile selected from the group consisting of: a circle, an oval, and an ellipse. 
Poklopac (104) prema barem jednom od prethodnih zahtjeva, naznačen time da otvor (108) ima profil koji je odabran iz skupine koju čine: krug, ovalni oblik, i elipsa.
The cap (104) of at least one of the preceding claims, wherein the sealing portion (124) includes one or more support ribs (134). 
Poklopac (104) prema barem jednom od prethodnih zahtjeva, naznačen time da brtveni dio (124) sadrži jedno ili više rebara (134).
The cap (104) of at least one of the preceding claims, wherein the sealing portion (124) includes a peripheral ring (127) having a stiffness that is less than a remainder of the sealing portion (124). 
Poklopac (104) prema barem jednom od prethodnih zahtjeva, naznačen time da brtveni dio (124) sadrži periferni prsten (127) koji ima krutost koja je manja od ostatka brtvenog dijela (124).
a container (102); and the cap (104) of at least one of the preceding claims coupled to the container (102). 
spremnik (102); i poklopac (104) prema barem jednom od prethodnih zahtjeva spojen na spremnik (102).
The pharmaceutical composition of claim 3 or 4, wherein said pharmaceutical composition is formulated for topical, parenteral, intravenous, intra-arterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, by suppositories, or oral administration. 
Farmaceutski pripravak prema zahtjevu 3 ili 4, naznačen time da je navedeni farmaceutski pripravak formuliran za lokalno, parenteralno, intravensko, intra-arterijsko, subkutano, intramuskularno, intrakranijalno, intraorbitalno, oftalmičko, intraventrikularno, intrakapsularno, intraspinalno, intracisternalno, intraperitonealno, intranazalno, putem aerosola, supozitorijama ili za oralno davanje.
The pharmaceutical composition for use according to any one of claims 6-12, wherein said fungal infection is selected from tinea capitis, tinea corporis, tinea pedis, onychomycosis, perionychomycosis, pityriasis versicolor, oral thrush, vaginal candidosis, respiratory tract candidosis, biliary candidosis, eosophageal candidosis, urinary tract candidosis, systemic candidosis, mucocutaneous candidosis, aspergillosis, mucormycosis, paracoccidioidomycosis, North American blastomycosis, histoplasmosis, coccidioidomycosis, sporotrichosis, fungal sinusitis, or chronic sinusitis. 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 6-12, naznačen time da je navedena gljivična infekcija izabrana između tinea glave, tinea tijela, atletskog stopala (tinea pedis), onikomikoze, perionikomikoze, pityriasis versicolor, oralne kandidijaze, vaginalne kandidijaze, kandidijaze dišnih puteva, bilijarne kandidijaze, ezofagusne kandidijaze, kandidijaze urinarnog trakta, sistemske kandidijaze, mukokutanozne kandidijaze, aspergiloze, mukormikoze, parakokcidioidomikoze, Južnoameričke blastomikoze, histoplazmoze, kokcidioidomikoze, sporotrihoze, gljivičnog sinusitisa, ili kroničnog sinusitisa.
The compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in preventing, stabilizing or inhibiting the growth of fungi, or killing fungi. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, za upotrebu u prevenciji, stabilizaciji ili inhibiciji rasta gljivica ili istrebljenju gljivica.
The syringe of claim 2, wherein the at least one tapered surface (40, 42) further comprises a second surface (42) tapered axially along the outer surface of the sidewall (19) in a direction opposite the first surface (40). 
Štrcaljka prema zahtjevu 2, naznačena time da barem jedna konusna površina (40, 42) dodatno obuhvaća drugu površinu (42) koja se sužava aksijalno duž vanjske površine bočne stjenke (19) u smjeru suprotnom od prve površine (40).
promoting cell death in a cancer cell in a patient; or 
poticanju stanične smrti u tumorskoj stanici kod pacijenta; ili
for use in treating cancer in a patient. 
za upotrebu u liječenju tumora kod pacijenta.
said cell is a cancer cell having a defect in the ATM signaling cascade or said cancer cell or cancer has a defect in the ATM signaling cascade; for example wherein said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, and SMC1; or 
navedena stanica predstavlja tumorsku stanicu koja ima defekt u ATM signalnoj kaskadi, ili navedena tumorska stanica ili tumor ima defekt u ATM signalnoj kaskadi; na primjer gdje naveden defekt predstavlja izmijenjenu ekspresiju ili aktivnost jednog ili više od sljedećeg: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, i SMC1; ili
The compound or a pharmaceutically acceptable salt thereof for use according to any one of claims 8-11, wherein said additional therapeutic agent is Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also known as BSI-201 or SAR240550), Veliparib (also known as ABT-888), Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or AZD2461. 
Spoj ili njegova farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 8-11, gdje je navedeno dodatno terapeutsko sredstvo Olaparib (također poznat kao AZD2281 ili KU-0059436), Iniparib (također poznat kao BSI-201 ili SAR240550), Veliparib (također poznat kao ABT-888), Rukaparib (također poznat kao PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, ili AZD2461.
in combination with an additional therapeutic agent, wherein said additional therapeutic agent inhibits a base excision repair protein; and wherein the base excision repair protein is PARP1 or PARP2; for use 
u kombinaciji sa dodatnim terapeutskim sredstvom, gdje navedeno dodatno terapeutsko sredstvo inhibira protein za reparaciju isijecanjem baza; i gdje je protein za reparaciju isijecanjem baza PARP1 ili PARP2; za upotrebu
as a radio-sensitizer or a chemo-sensitizer in a patient; or 
kao radiosenzibilizator ili hemosenzibilizator kod pacijenta; ili
The compound or a pharmaceutically acceptable salt thereof for use according to any one of claims 1-7, wherein said cell or cancer cell is a cell selected from the group consisting of oral cancer cell, cardiac cancer cell, lung cancer cell, gastrointestinal cancer cell, genitourinary tract cancer cell, liver cancer cell, bone cancer cell, nervous system cancer cell, gynecological cancer cell, skin cancer cell, thyroid gland cancer cell, and adrenal glands cancer cell; for example, wherein said cell or cancer cell is a cell from an oral cancer selected from the group consisting of: buccal cavity cancer, lip cancer, tongue cancer, mouth cancer, and pharyngeal cancer; wherein said cell or cancer cell is a cell from a cardiac cancer selected from the group consisting of: sarcomas (angiosarcomas, fibrosarcomas, rhabdomyosarcomas, liposarcomas), myxomas, rhabdomyomas, fibromas, lipomas, and teratomas; 
Spoj ili njegova farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 1-7, gdje navedena stanica ili tumorska stanica predstavlja stanicu izabranu iz grupe koja se sastoji od stanice oralnog tumora, stanice tumora srca, stanice tumora pluća, stanice gastrointestinalnog tumora, stanice tumora genitourinarnog trakta, stanice tumora jetre, stanice tumora kosti, stanice tumora živčanog sustava, stanice ginekološkog tumora, stanice tumora kože, stanice tumora tiroidne žljezde i stanice tumora adrenalne žljezde; na primjer, gdje navedena stanica ili tumorska stanica predstavlja stanicu iz oralnog tumora izabranu iz grupe koja se sastoji od: tumora bukalne šupljine, tumora usne, tumora jezika, tumora usta, i faringealnog tumora; gdje navedena stanica ili tumorska stanica predstavlja stanicu iz tumora srca izabranu iz grupe koja se sastoji od: sarkoma (angiosarkoma, fibrosarkoma, rabdomiosarkoma, liposarkoma), miksoma, rabdomioma, fibroma, lipoma, i teratoma;
wherein said cell or cancer cell is a cell from a lung cancer selected from the group consisting of: bronchogenic carcinomas (squamous cell, epidermoid carcinoma, undifferentiated small cell carcinomas, undifferentiated large cell carcinoma, adenocarcinomas), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma; 
gdje navedena stanica ili tumorska stanica predstavlja stanicu iz tumora pluća izabranu iz grupe koja se sastoji od: bronhogenih karcinoma (skvamoznih stanica, epidermoidnog karcinoma, nediferenciranih karcinoma malih stanica, nediferenciranih karcinoma velikih stanica, adenokarcinoma), alveolarnog (bronhiolarnog) karcinoma, bronhijalnog adenoma, sarkoma, limfoma, hondromatoznog hamartoma, i mezotelioma;
wherein said cell or cancer cell is a cell from is a bone cancer selected from the group consisting of: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors; 
gdje navedena stanica ili tumorska stanica predstavlja stanicu iz tumora kosti izabrana iz grupe koja se sastoji od: osteogenog sarkoma (osteosarkoma), fibrosarkoma, malignog fibroznog histiocitoma, hondrosarkoma, Juingovog sarkoma, malignog limfoma (sarkoma retikularnih stanica), multiplog mijeloma, malignog tumora hordoma s gigantskim stanicama, osteohondroma (koštano-hrskavičave egzostoze), benignog hondroma, hondroblastoma, hondromiksofibroma, osteoidnog osteoma, i tumora gigantskih stanica;
wherein said cell or cancer cell is a cell from a nervous system cancer selected from the group consisting of: skull cancer (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meningeal cancer (meningioma, meningiosarcoma, gliomatosis), brain cancer (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord cancer, neurofibroma, meningioma, glioma, and sarcoma; 
gdje navedena stanica ili tumorska stanica predstavlja stanicu iz tumora živčanog sustava izabranu iz grupe koja se sastoji od: tumora lubanje (osteoma, hemangioma, granuloma, ksantoma, osteitisa deformansa), meningealnog tumora (meningioma, meningiosarkoma, gliomatoze), tumora mozga (astrocitoma, meduloblastoma, glioma, ependimoma, germinoma [pinealoma], multiformnog glioblastoma, oligodendroglioma, švanoma, retinoblastoma, kongenitalnih tumora), tumora leđne moždine, neurofibroma, meningioma, glioma, i sarkoma;
The compound or a pharmaceutically acceptable salt thereof for use according to any one of claims 8-12, wherein said cancer is a solid tumor selected from the group consisting of: oral cancer, cardiac cancer, lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, skin cancer, thyroid gland cancer, or adrenal gland cancer; for example, wherein said cancer is an oral cancer selected from the group consisting of: buccal cavity cancer, lip cancer, tongue cancer, mouth cancer, and pharyngeal cancer; 
Spoj ili njegova farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 8-12, gdje je naveden tumor solidni tumor izabran iz grupe koja se sastoji od: oralnog tumora, tumora srca, tumora pluća, gastrointestinalnog tumora, tumora genitourinarnog trakta, tumora jetre, tumora kosti, tumora živčanog sustava, ginekološkog tumora, tumora kože, tumora tiroidne žljezde i tumora adrenalne žljezde; na primjer, gdje naveden tumor predstavlja oralni tumor izabran iz grupe koja se sastoji od: tumora bukalne šupljine, tumora usne, tumora jezika, tumora usta, i faringealnog tumora;
wherein said cancer is a lung cancer selected from the group consisting of: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma; 
gdje naveden tumor predstavlja tumor pluća izabran iz grupe koja se sastoji od: bronhogenih karcinoma (skvamoznih stanica, epidermoidnog karcinoma, nediferenciranih karcinoma malih stanica, nediferenciranih karcinoma velikih stanica, adenokarcinoma), alveolarnog (bronhiolarnog) karcinoma, bronhijalnog adenoma, sarkoma, limfoma, hondromatoznog hamartoma, i mezotelioma;
wherein said cancer is a skin cancer selected from the group consisting of: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, and dermatofibroma; 
gdje naveden tumor predstavlja tumor kože izabran iz grupe koja se sastoji od: malignog melanoma, karcinoma bazalnih stanica, karcinoma skvamoznih stanica, Karpošijevog sarkoma, keratoakantoma, displastičnih mladeža, lipoma, angioma, i dermatofibroma;